Palatin Technologies Inc
F:PTN

Watchlist Manager
Palatin Technologies Inc Logo
Palatin Technologies Inc
F:PTN
Watchlist
Price: 3.3 EUR Market Closed
Market Cap: 34m EUR

During the last 3 months Palatin Technologies Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on May 7, 2025 by Deveer Robert K Jr , who bought 10.2k EUR worth of PTN shares.

Last Transactions:
Deveer Robert K Jr
€+4.1
Wills Stephen T
€-4.1k
Deveer Robert K Jr
€+12.7k
Deveer Robert K Jr
€-3.4k
Wills Stephen T
€-6.8k
Dunton Alan W
€-493.5
Wills Stephen T
€+5.8k
Spana Carl
€+11.2k
Dunton Alan W
€-594
Hull Joseph Stanley
€+244
Dunton Alan W
€+246
Spana Carl
€+1.6k
Deveer Robert K Jr
€+885.6
Deveer Robert K Jr
€-999.2
Hull Joseph Stanley
€+25.1
Spana Carl
€+690.4
Deveer Robert K Jr
€+776.6
Wills Stephen T
€+1.7k
Spana Carl
€+344
Morris Arlene
€+263.1
Dunton Alan W
€+156
Wills Stephen T
€+152.2
Spana Carl
€+630.6
Dunton Alan W
€+10.4
Hull Joseph Stanley
€+66.1
Hull Joseph Stanley
€+52.2
Deveer Robert K Jr
€+326.8
View All Transactions

During the last 3 months Palatin Technologies Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on May 7, 2025 by Deveer Robert K Jr , who bought 10.2k EUR worth of PTN shares.

Sold
0-3
months
0 EUR
0
3-6
months
0 EUR
0
6-9
months
0 EUR
0
9-12
months
0 EUR
0
Bought
0-3
months
No Insider Transactions
0
0 EUR
3-6
months
No Insider Transactions
0
0 EUR
6-9
months
1
4.1 EUR
9-12
months
No Insider Transactions
0
0 EUR

Palatin Technologies Inc
Insider Trading Chart

Palatin Technologies Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Palatin Technologies Inc
Last Insider Transactions

Global
Insiders Monitor

Palatin Technologies Inc
Glance View

Market Cap
34m EUR
Industry
Biotechnology

Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector. Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.

PTN Intrinsic Value
0.13 EUR
Overvaluation 96%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top